Figure 5.
Clonal relapse dynamics of patients based on detectable DTA and non-DTA molecular markers. Relapse DTA (DNMT3A, TET2, ASXL1) and non-DTA mutations were, if possible, repetitively monitored by NGS-MRD. Total number of prerelapse NGS analyses of DTA mutations: n = 69; median, 1; range, 1-5. Total number of prerelapse NGS analyses of non-DTA-mutations: n = 227; median, 1; range, 1-6. f(x)=0.98+0.5x+0.13x2+0.02x3−0.0009x4−0.00002x5, f(xDTA)=0.97+0.4xDTA+0.06xDTA2+0.005xDTA3−0.0002xDTA4−0.00002xDTA5.

Clonal relapse dynamics of patients based on detectable DTA and non-DTA molecular markers. Relapse DTA (DNMT3A, TET2, ASXL1) and non-DTA mutations were, if possible, repetitively monitored by NGS-MRD. Total number of prerelapse NGS analyses of DTA mutations: n = 69; median, 1; range, 1-5. Total number of prerelapse NGS analyses of non-DTA-mutations: n = 227; median, 1; range, 1-6. f(x)=0.98+0.5x+0.13x2+0.02x30.0009x40.00002x5, f(xDTA)=0.97+0.4xDTA+0.06xDTA2+0.005xDTA30.0002xDTA40.00002xDTA5.

or Create an Account

Close Modal
Close Modal